A-431 nuclear extract (EGF treated)

Catalog No: 36003 Format: 200 µg ¥44,000 Buy

Contents

200 µg of A-431 nuclear extract (EGF treated) at 2.5 µg/µl.

Background

A-431 nuclear extract (EGF treated) was prepared from cell cultures of the human epidermoid carcinoma A431 cell line. These cells are characterized by abnormally high levels of expression of epidermal growth factor receptor (EGFR), approximately 3 x 106/cell, on the cell surface and exhibits a biphasic response to varying concentrations of epidermal growth factor (EGF). Specifically, lower (pmol) concentrations of EGF stimulates cell growth while higher (nmol) concentrations inhibits cell growth and induces terminal differentiation. Therefore, these cells are commonly used as a positive control for EGFR expression and in studies of EGFR downstream signaling cascades. These cells are also highly responsive to mitogenic stimuli and are naturally devoid of p53, so are frequently used in cancer and cell cycle-associated studies.

Application Notes

A-431 nuclear extract (EGF treated) is specifically recommended for analysis of 1) EGFR expression and downstream signaling cascades, 2) cell cycle, and 3) cancer-associated signaling pathways.

Extract Origin

Human Epidermoid Carcinoma

Extract Composition

A-431 nuclear extract (EGF treated) is supplied in Dilution Buffer (20 mM Hepes (pH 7.9), 100 mM KCl, 1 mM MgCl2, 20% glycerol, 0.5 mM PMSF and 0.5 mM DTT). Cells were cultured in medium supplemented with 10 ng/ml EGF (epidermal growth factor) for 10 minutes at 37°C immediately prior to harvesting.

Quality Control

Extracts have been quality control tested by Western blot.

Storage

To ensure stability, extracts should be stored at -80°C.

We recommend aliquoting the extracts into single-use fractions and then storing them at -80°C. This eliminates repeated freeze/thaw cycles.

Guarantee

This product is guaranteed for 6 months from date of receipt.

This product is for research use only and is not for use in diagnostic procedures.